Assessing the role of Chemokine (C-C motif) ligand 14 in AKI : a European consensus meeting
Koyner, Jay L. (University of Chicago)
Arndt, Christian (Anesthesiology and Intensive Care Medicine. Philipps-Universitat Marburg Fachbereich Medizin)
Baldira Martínez de Irujo, Jaume (Institut de Recerca Sant Pau)
Coelho, Sílvia (Hospital Fernando da Fonseca EPE)
Garcia-Montesinos de la Peña, Manuel (Clínica Universidad de Navarra)
di Girolamo, Luca (IRCCS Policlinico San Donato (Itàlia))
Joannidis, Michael (Medical Unversity Innsbruck)
Jorge-Monjas, Pablo (Hospital Clínico Universitario de Valladolid)
Koch, Christian (Justus Liebig University of Giessen)
Lobaz, Steven (Barnsley Hospital NHS Foundation Trust)
Meyer, Alain (University Hospital of Strasbourg)
Ostermann, Marlies (St Guy's and St Thomas' Hospital (Londres, Regne Unit))
Pertica, Nicoletta (University Hospital of Verona (Itàlia))
Prowle, Jhon R. (Queen Mary University (Londres, Regne Unit))
Silversides, Jon (Queen's University (Belfast, Regne Unit))
Zarbock, Alexander (University Hospital of Münster (Alemanya))
Echeverri Cifuentes, Juan (Baxter Healthcare Corporation (Deerfield, Estats Units d'Amèrica))
Harenski, Kai (Baxter Deutschland GmbH (Unterschleissheim, Alemanya))
Forni, Lui G. (University of Surrey (Guildford, Regne Unit))
Universitat Autònoma de Barcelona

Data:	2024
Resum:	Background: Urinary Chemokine (C-C motif) ligand 14 (CCL14) is a biomarker associated with persistent severe acute kidney injury (AKI). There is limited data to support the implementation of this AKI biomarker to guide therapeutic actions. Methods: Sixteen AKI experts with clinical CCL14 experience participated in a Delphi-based method to reach consensus on when and how to potentially use CCL14. Consensus was defined as ≥ 80% agreement (participants answered with 'Yes', or three to four points on a five-point Likert Scale). Results: Key consensus areas for CCL14 test implementation were: identifying challenges and mitigations, developing a comprehensive protocol and pairing it with a treatment plan, and defining the target population. The majority agreed that CCL14 results can help to prioritize AKI management decisions. CCL14 levels above the high cutoff (> 13 ng/mL) significantly changed the level of concern for modifying the AKI treatment plan (p < 0. 001). The highest level of concern to modify the treatment plan was for discussions on renal replacement therapy (RRT) initiation for CCL14 levels > 13 ng/mL. The level of concern for discussion on RRT initiation between High and Low, and between Medium and Low CCL14 levels, showed significant differences. Conclusion: Real world urinary CCL14 use appears to provide improved care options to patients at risk for persistent severe AKI. Experts believe there is a role for CCL14 in AKI management and it may potentially reduce AKI-disease burden. There is, however, an urgent need for evidence on treatment decisions and adjustments based on CCL14 results.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Biomarker testing experience ; C-C motif chemokine ligand 14 (CCL14) ; Consensus ; Critical care nephrology ; Persistent acute kidney injury
Publicat a:	Renal Failure, Vol. 46 Núm. 1 (2024) , p. 2345747, ISSN 1525-6049

DOI: 10.1080/0886022X.2024.2345747
PMID: 38666354

8 p, 1.0 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats